An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment

Trial Profile

An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs R-phenserine (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors QR Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 13 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top